Company Overview and News

0
Cellmid expanding products, portfolio and markets; and approaching profitablity

2018-08-01 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) CEO Maria Halasz speaks to Proactive Investors about the company's diversified and global operations, and recent cash raise.
CDY

0
Cellmid raises $9 million for distribution and invites shareholders to invest $1 million

2018-07-31 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) has raised $9 million from sophisticated and institutional investors and will invite shareholders to participate in a $1 million share placement plan.
CDY

0
Cellmid granted ASX trading halt prior to capital raising news

2018-07-27 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) has been granted an ASX trading halt before releasing details of a proposed capital raising.
CDY

0
Cellmid lays out major plan for product and distribution expansion

2018-07-11 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) is anticipating a substantial increase in revenue in FY2019 following the planned expansion of distribution in the US and Japan and the increase in products in Australia.
CDY

0
Cellmid set to launch its évolis hair care products in the lucrative Chinese market

2018-05-02 proactiveinvestors.com.au
Cellmid Limited’s (ASX:CDY) wholly owned subsidiary Advangen has entered into an exclusive agreement to distribute its évolis® anti-aging hair care products in the Peoples Republic of China.
CDY

19
Cellmid secures partnership with Bloomingdales to sell évolis®

2018-04-24 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has secured a new premium retail partnership with leading US retailer, Bloomingdales, for its évolis® Professional product range.
CDY M

0
Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

2018-04-23 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) has reported a record quarter of receipts of $2.2 million in the three months ending March 31, 2018.
CDY

0
Cellmid gaining ground in USA and China following advances in Japan and Australia

2018-04-12 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) CEO Maria Halasz provides a show and tell updating Proactive Investors on progress and strategies for the company’s international portfolio of products, including the world’s first non-injectable filler product.
CDY

0
Cellmid convening global meeting of midkine researchers in Germany

2018-04-09 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.
CDY

0
Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

2018-04-04 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) is one of the more diversified ASX-listed biopharmaceutical groups with prominent products in the health and well-being sectors as well as traditional clinical markets.
CDY

0
Cellmid enters exclusive distribution agreement for anti-ageing skincare product

2018-04-04 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina® in Australia and New Zealand for an initial period of up to five years.
CDY

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...